Methimazole
Methimazole (methimazole) is a small molecule pharmaceutical. Methimazole was first approved as Tapazole on 1982-01-01. It is used to treat goiter and thyroid crisis in the USA. The pharmaceutical is active against thyroid peroxidase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Methimazole (discontinued: Methimazole, Tapazole)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Methimazole
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TAPAZOLE | King Pharmaceuticals | N-007517 DISCN | 1982-01-01 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| methimazole | ANDA | 2025-09-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| goiter | EFO_0004283 | D006042 | E04.9 |
| thyroid crisis | EFO_1001212 | D013958 | E05.5 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
38 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graves disease | D006111 | EFO_0004237 | E05.0 | 1 | 3 | 3 | 5 | 14 | 24 |
| Recurrence | D012008 | — | — | 1 | — | — | 2 | — | 3 |
| Eye diseases | D005128 | EFO_0003966 | H44 | 1 | 1 | — | 1 | 1 | 3 |
| Goiter | D006042 | EFO_0004283 | E04.9 | — | — | — | 2 | 1 | 3 |
| Healthy volunteers/patients | — | — | — | — | — | — | 1 | — | 1 |
| Substance withdrawal syndrome | D013375 | EFO_0005800 | — | — | — | — | 1 | — | 1 |
| Therapeutics | D013812 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperthyroidism | D006980 | — | E05.9 | 1 | — | 1 | — | 9 | 11 |
| Graves ophthalmopathy | D049970 | EFO_1001466 | — | 1 | 1 | 2 | — | 1 | 4 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | 1 | — | — | 1 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 1 | — | — | 1 |
| Pathologic processes | D010335 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | 2 | — | — | — | 3 |
| Thyroid diseases | D013959 | — | E00-E07 | 1 | 2 | — | — | 1 | 3 |
| Thyrotoxicosis | D013971 | — | E05 | — | 1 | — | — | 1 | 2 |
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | 1 | 1 | — | — | — | 1 |
| Myositis | D009220 | EFO_0000783 | G72.49 | — | 1 | — | — | — | 1 |
| Dermatomyositis | D003882 | EFO_0000398 | M33 | — | 1 | — | — | — | 1 |
| Polymyositis | D017285 | EFO_0003063 | M33.2 | — | 1 | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanosis | D008548 | EFO_0003963 | L81.1 | 1 | — | — | — | — | 1 |
| Gliosarcoma | D018316 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hashimoto disease | D050031 | EFO_0003779 | E06.3 | — | — | — | — | 2 | 2 |
| Microbiota | D064307 | — | — | — | — | — | — | 2 | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Gastrointestinal microbiome | D000069196 | — | — | — | — | — | — | 1 | 1 |
| Patient acceptance of health care | D010342 | — | — | — | — | — | — | 1 | 1 |
| Congenital hypothyroidism | D003409 | — | E00.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Methimazole |
| INN | thiamazole |
| Description | Methimazole is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen. It has a role as an antithyroid drug. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cn1ccnc1S |
Identifiers
| PDB | — |
| CAS-ID | 60-56-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1515 |
| ChEBI ID | 50673 |
| PubChem CID | 1349907 |
| DrugBank | DB00763 |
| UNII ID | 554Z48XN5E (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Methimazole
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,567 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,342 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use